Aclarion Announces New Engagement with The London Clinic and London Spine Clinic
May 30, 2023 07:30 ET
|
Aclarion, Inc.
The London Clinic is the UK’s most renowned independent, private hospital, established 1932. The London Spine Clinic is first specialist spinal unit established in England, 1997. The London...
Aclarion’s Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD
May 23, 2023 07:30 ET
|
Aclarion, Inc.
Development of This Program Supports Aclarion’s Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key Opinion Leader Advocacy Aclarion to Participate in...
Aclarion, Inc. Announces Delayed 10-Q Filing
May 23, 2023 07:00 ET
|
Aclarion, Inc.
BROOMFIELD, CO, May 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers...
Aclarion Announces Non-Convertible Debt Financing to Achieve Three Critical Catalysts
May 19, 2023 07:30 ET
|
Aclarion, Inc.
Up to $2M Unsecured, Non-Convertible Bridge Debt With No Required Amortization Payments Financing Supports Execution of the 2023 Plan and the Achievement of Critical Milestones in Support of...
Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain
May 02, 2023 07:00 ET
|
Aclarion, Inc.
Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market,...
Aclarion to Host Thought Leadership Symposium at SPINEWEEK 2023
April 28, 2023 11:20 ET
|
Aclarion, Inc.
Nociscan™ is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological low back pain. Nociscan provides decision support to help bridge a...
Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial
April 24, 2023 07:00 ET
|
Aclarion, Inc.
Success rate at 2 years for discogenic low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over...
Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor
March 07, 2023 09:19 ET
|
Aclarion, Inc.
Marks the eighth advisor to growing KOL program to build strong body of clinical evidence and support US commercialization Aclarion to participate in upcoming SPINEWEEK 2023 Broomfield,...
Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium
February 15, 2023 07:00 ET
|
Aclarion, Inc.
NociscanTM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain. Nociscan provides decision support to help bridge a...
Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor
January 31, 2023 10:01 ET
|
Aclarion, Inc.
Director of Endoscopic Spine Surgery at the University of Miami Broomfield, CO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq:...